Tirzepatide 10mg 30mg

Tirzepatide 10mg 30mg is the world's first GIP/GLP-1 dual receptor agonist peptide active pharmaceutical ingredient, composed of 39 amino acids. It is refined using advanced solid-phase synthesis and purification techniques, achieving a purity ≥98% and bioavailability ≥95%.

Unlike traditional single-target GLP-1 analogs, this product integrates the activation capabilities of both GIP and GLP-1 pathways in its molecular structure, exhibiting a synergistic mechanism. This structural characteristic allows it to display a differentiated in vitro activity spectrum in terms of receptor binding affinity and metabolic regulation, providing a broader window for pharmacodynamic modulation in formulation development.

As a dual-target agonist active ingredient, this product can simultaneously activate both GIP and GLP-1 receptors at the molecular level, exerting a synergistic signal transduction effect. Compared to single GLP-1 target agonists, dual-pathway activation has demonstrated superior insulin secretion-promoting and glucagon-inhibiting effects in in vitro studies, with a broader metabolic regulatory spectrum.

Current research data shows that the main adverse reactions of the active ingredient in clinical studies are mild gastrointestinal reactions (nausea, diarrhea, etc.), which are mostly transient and reversible. The incidence of GLP-1-related adverse reactions is lower than that of similar single-target active ingredients. This product is for research and drug development purposes only, suitable for studies on the mechanism of action of dual-receptor agonists, formulation development, comparative studies of generic drug quality, and optimization of manufacturing processes.

Raw Material Advantages:

• Long-lasting design: Optimized molecular structure significantly prolongs the half-life in plasma, making it suitable for once-weekly dosing formulations.
• Glucose concentration-dependent: Insulin secretion stimulation is glucose concentration-dependent, and in vitro studies show a low risk of hypoglycemia.
• Multiple metabolic regulation: Demonstrates dual activity in preclinical models, promoting weight loss and improving glycemic control.

• Drug Development and Formulation Research - As a GIP/GLP-1 dual-receptor agonist active pharmaceutical ingredient (API), it is suitable for formulation screening and development of novel formulations in the field of metabolic diseases, supporting formulation research and process optimization for different dosage forms such as injections, sustained-release microspheres, and peptide conjugates.

   

• Scientific Research and Mechanism Exploration - Applicable to dual-receptor agonist pathway research, in vitro cell model activity evaluation, and in vivo pharmacodynamics and pharmacokinetic experiments. Customizable purity up to 99.8%, providing small-size packaging to meet the needs of refined experiments.

• OEM/ODM Customization Services - Supporting contract manufacturing collaborations for finished formulations, providing multi-specification API repackaging from 5mg to 50mg/vial and multilingual label customization to help brands quickly enter target markets.

1.Full-Process Quality Control System

① Raw Material Incoming Inspection - API identification, content, related substances, and residual solvent testing; functional verification of excipients and packaging materials.

② Production Process Control - Real-time monitoring of synthesis/purification, control of intermediate impurities, and monitoring of the production environment and water quality.

③ Finished Product Release Testing - Purity (HPLC ≥ 98%), microbiology (sterility/endotoxin/limits), heavy metals/residual solvents (ICP-MS/GC-MS), and physicochemical indicators (moisture/pH/osmolarity/dosage accuracy).

2.Testing Equipment and Laboratory Capabilities

Equipped with advanced instruments such as HPLC, LC-MS/MS, GC-MS, ICP-MS, and SEC, all equipment is calibrated and has audit trail capabilities. The laboratory is cGMP/ISO 22000 certified and possesses capabilities for method validation, stability studies, and data integrity management.

3.Third-Party Collaboration and Quality Assurance

Collaborating with government laboratories and certified CROs for result verification and comparability analysis with original drugs. Each batch of products is accompanied by a Certificate of Authorization (CoA), ensuring product quality across the entire chain, from safety and stability to testing systems, laboratory capabilities, and third-party verification.

4.Test Items and Specifications 

• Dual-Target Technology Barrier: Exclusively optimizes the dual receptor activation ratio, ensuring 15% higher efficacy than ordinary raw materials, with patented purification technology.
• Risk-Free Trial & Flexible Supply: Provides 5 free samples (delivery in 3-7 days) with a low MOQ of 10 boxes. Supports customization of 5-50mg/vial specifications to avoid inventory backlogs.
• Global Compliance Assurance: Offers a full set of compliant documents (COA/GMP Certificate/SDS), meeting EU, US and Chinese standards. A dedicated team assists with regional customs clearance, ensuring zero compliance risks.
• Cost-Effective Factory Direct Supply: Saving 8%-12% of costs compared to traders, with excellent batch-to-batch purity stability.
• One-Stop Value-Added Services: 12-hour professional response, one-on-one injection formulation guidance, and unconditional return for quality issues to accelerate your product launch.

• For research/medical/OEM use only. Not for direct human consumption or clinical treatment. Regional dosage standards must be followed.
• This product should be kept away from strong oxidizing agents to prevent chemical reactions that could lead to deterioration. Store in a sealed, cool, dry, and dark place, with a recommended storage temperature of 2°C–8°C (refrigerated). Once opened, use within 7 days. Any unused portion should be disposed of properly according to regulations and must not be resealed for future use.
• Strictly prohibited for prohibited areas (e.g., illegal weight loss products). We are not liable for disputes arising from improper use.